{"id":66748,"date":"2026-05-29T21:49:59","date_gmt":"2026-05-29T13:49:59","guid":{"rendered":"https:\/\/flcube.com\/?p=66748"},"modified":"2026-05-29T21:50:00","modified_gmt":"2026-05-29T13:50:00","slug":"shionogis-symproic-naldemedine-receives-nmpa-approval-for-opioid-induced-constipation-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66748","title":{"rendered":"Shionogi&#8217;s Symproic (Naldemedine) Receives NMPA Approval for Opioid-Induced Constipation in China"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Shionogi &amp; Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/4507:TYO\">TYO: 4507<\/a>) announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has granted <strong>marketing approval<\/strong> for <strong>Symproic (naldemedine)<\/strong>, an <strong>opioid-induced constipation (OIC) therapy<\/strong>. Naldemedine represents the <strong>world&#8217;s first approved oral, peripherally acting selective mu-opioid receptor antagonist (PAMORA)<\/strong> and is now registered across major global markets including China, the United States, European Union, United Kingdom, and Japan.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone-amp-global-registration-status\" class=\"wp-block-heading\">Regulatory Milestone &amp; Global Registration Status<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Regulatory Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Marketing authorization<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Opioid-induced constipation (OIC)<\/td><\/tr><tr><td><strong>Global Registration<\/strong><\/td><td>\u2713 China (including Hong Kong, Macau, Taiwan)<br>\u2713 United States<br>\u2713 European Union<br>\u2713 United Kingdom<br>\u2713 Japan<\/td><\/tr><tr><td><strong>Guideline Recognition<\/strong><\/td><td>American College of Gastroenterology (AGA)<br>European Society for Medical Oncology (ESMO)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Drug Class:<\/strong> Oral, peripherally acting selective mu-opioid receptor antagonist (PAMORA)<\/li>\n\n\n\n<li><strong>Innovation Status:<\/strong> <strong>World&#8217;s first approved oral PAMORA<\/strong><\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Blocks binding of opioids to mu receptors in the gut<\/li>\n\n\n\n<li><strong>Physiological Effects:<\/strong><\/li>\n\n\n\n<li>Restores normal intestinal peristalsis<\/li>\n\n\n\n<li>Normalizes fluid secretion in gastrointestinal tract<\/li>\n\n\n\n<li><strong>Fundamentally reverses OIC pathophysiology<\/strong> at receptor level<\/li>\n\n\n\n<li><strong>Selectivity Advantage:<\/strong> Peripheral action minimizes central nervous system effects<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-significance-amp-market-context\" class=\"wp-block-heading\">Clinical Significance &amp; Market Context<\/h2>\n\n\n\n<h3 id=\"h-opioid-induced-constipation-burden\" class=\"wp-block-heading\">Opioid-Induced Constipation Burden<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient Population:<\/strong> Millions of chronic pain patients worldwide requiring opioid therapy<\/li>\n\n\n\n<li><strong>Prevalence:<\/strong> OIC affects 40-60% of patients on chronic opioid therapy<\/li>\n\n\n\n<li><strong>Current Treatment Limitations:<\/strong> Traditional laxatives address symptoms but not underlying mechanism<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> Targeted therapy that specifically addresses opioid receptor-mediated constipation<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-competitive-pamora-landscape\" class=\"wp-block-heading\">Competitive PAMORA Landscape<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Company<\/th><th>China Status<\/th><th>Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>Naldemedine (Symproic)<\/strong><\/td><td>Shionogi<\/td><td><strong>NMPA approved<\/strong><\/td><td><strong>World&#8217;s first oral PAMORA, global guideline recognition<\/strong><\/td><\/tr><tr><td><strong>Methylnaltrexone<\/strong><\/td><td>Salix\/Valeant<\/td><td>Approved<\/td><td>Subcutaneous administration only<\/td><\/tr><tr><td><strong>Naloxegol<\/strong><\/td><td>AstraZeneca<\/td><td>Not approved in China<\/td><td>Limited global availability<\/td><\/tr><tr><td><strong>Traditional Laxatives<\/strong><\/td><td>Various generics<\/td><td>Widely available<\/td><td>Symptomatic relief only, no mechanistic action<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-market-implications\" class=\"wp-block-heading\">Strategic Market Implications<\/h2>\n\n\n\n<h3 id=\"h-for-shionogi-amp-co\" class=\"wp-block-heading\">For Shionogi &amp; Co.<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Market Entry:<\/strong> Completes global commercial footprint for flagship PAMORA product<\/li>\n\n\n\n<li><strong>Revenue Expansion:<\/strong> Access to world&#8217;s largest population of chronic pain patients<\/li>\n\n\n\n<li><strong>Guideline Leverage:<\/strong> AGA and ESMO recommendations support rapid physician adoption<\/li>\n\n\n\n<li><strong>Pricing Strategy:<\/strong> Premium positioning justified by mechanistic superiority over traditional approaches<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-china-pain-management-market-dynamics\" class=\"wp-block-heading\">China Pain Management Market Dynamics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Opioid Usage Growth:<\/strong> Increasing acceptance of opioid therapy for cancer and chronic non-cancer pain<\/li>\n\n\n\n<li><strong>Healthcare Infrastructure:<\/strong> Growing number of pain clinics and palliative care centers<\/li>\n\n\n\n<li><strong>Regulatory Environment:<\/strong> NMPA approval reflects recognition of significant unmet medical need<\/li>\n\n\n\n<li><strong>Reimbursement Potential:<\/strong> High clinical value may support inclusion in national reimbursement drug list<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-commercial-outlook-amp-implementation-strategy\" class=\"wp-block-heading\">Commercial Outlook &amp; Implementation Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Launch Timeline:<\/strong> Expected Q3-Q4 2026<\/li>\n\n\n\n<li><strong>Target Prescribers:<\/strong> Oncologists, pain specialists, palliative care physicians<\/li>\n\n\n\n<li><strong>Education Initiative:<\/strong> Physician training on OIC diagnosis and PAMORA mechanism<\/li>\n\n\n\n<li><strong>Distribution Network:<\/strong> Leveraging existing Shionogi China infrastructure and potential partnerships<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding market launch, commercial performance, and regulatory compliance for Symproic (naldemedine). Actual results may differ due to risks including market competition, pricing negotiations, healthcare policy changes, and evolving treatment guidelines for opioid-induced constipation.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shionogi &amp; Co., Ltd. (TYO: 4507) announced that China&#8217;s National Medical Products Administration (NMPA) has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":66750,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[15,423,2673],"class_list":["post-66748","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-product-approvals","tag-shionogi","tag-tyo-4507"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shionogi&#039;s Symproic (Naldemedine) Receives NMPA Approval for Opioid-Induced Constipation in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shionogi &amp; Co., Ltd. (TYO: 4507) announced that China&#039;s National Medical Products Administration (NMPA) has granted marketing approval for Symproic (naldemedine), an opioid-induced constipation (OIC) therapy. Naldemedine represents the world&#039;s first approved oral, peripherally acting selective mu-opioid receptor antagonist (PAMORA) and is now registered across major global markets including China, the United States, European Union, United Kingdom, and Japan.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66748\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shionogi&#039;s Symproic (Naldemedine) Receives NMPA Approval for Opioid-Induced Constipation in China\" \/>\n<meta property=\"og:description\" content=\"Shionogi &amp; Co., Ltd. (TYO: 4507) announced that China&#039;s National Medical Products Administration (NMPA) has granted marketing approval for Symproic (naldemedine), an opioid-induced constipation (OIC) therapy. Naldemedine represents the world&#039;s first approved oral, peripherally acting selective mu-opioid receptor antagonist (PAMORA) and is now registered across major global markets including China, the United States, European Union, United Kingdom, and Japan.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66748\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-29T13:49:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-29T13:50:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2901-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66748#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66748\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shionogi&#8217;s Symproic (Naldemedine) Receives NMPA Approval for Opioid-Induced Constipation in China\",\"datePublished\":\"2026-05-29T13:49:59+00:00\",\"dateModified\":\"2026-05-29T13:50:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66748\"},\"wordCount\":470,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66748#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/2901-1.webp\",\"keywords\":[\"Product approvals\",\"Shionogi\",\"TYO: 4507\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66748#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66748\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66748\",\"name\":\"Shionogi's Symproic (Naldemedine) Receives NMPA Approval for Opioid-Induced Constipation in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66748#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66748#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/2901-1.webp\",\"datePublished\":\"2026-05-29T13:49:59+00:00\",\"dateModified\":\"2026-05-29T13:50:00+00:00\",\"description\":\"Shionogi & Co., Ltd. (TYO: 4507) announced that China's National Medical Products Administration (NMPA) has granted marketing approval for Symproic (naldemedine), an opioid-induced constipation (OIC) therapy. Naldemedine represents the world's first approved oral, peripherally acting selective mu-opioid receptor antagonist (PAMORA) and is now registered across major global markets including China, the United States, European Union, United Kingdom, and Japan.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66748#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66748\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66748#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/2901-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/2901-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Shionogi's Symproic (Naldemedine) Receives NMPA Approval for Opioid-Induced Constipation in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66748#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shionogi&#8217;s Symproic (Naldemedine) Receives NMPA Approval for Opioid-Induced Constipation in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shionogi's Symproic (Naldemedine) Receives NMPA Approval for Opioid-Induced Constipation in China - Insight, China&#039;s Pharmaceutical Industry","description":"Shionogi & Co., Ltd. (TYO: 4507) announced that China's National Medical Products Administration (NMPA) has granted marketing approval for Symproic (naldemedine), an opioid-induced constipation (OIC) therapy. Naldemedine represents the world's first approved oral, peripherally acting selective mu-opioid receptor antagonist (PAMORA) and is now registered across major global markets including China, the United States, European Union, United Kingdom, and Japan.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66748","og_locale":"en_US","og_type":"article","og_title":"Shionogi's Symproic (Naldemedine) Receives NMPA Approval for Opioid-Induced Constipation in China","og_description":"Shionogi & Co., Ltd. (TYO: 4507) announced that China's National Medical Products Administration (NMPA) has granted marketing approval for Symproic (naldemedine), an opioid-induced constipation (OIC) therapy. Naldemedine represents the world's first approved oral, peripherally acting selective mu-opioid receptor antagonist (PAMORA) and is now registered across major global markets including China, the United States, European Union, United Kingdom, and Japan.","og_url":"https:\/\/flcube.com\/?p=66748","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-29T13:49:59+00:00","article_modified_time":"2026-05-29T13:50:00+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2901-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66748#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66748"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shionogi&#8217;s Symproic (Naldemedine) Receives NMPA Approval for Opioid-Induced Constipation in China","datePublished":"2026-05-29T13:49:59+00:00","dateModified":"2026-05-29T13:50:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66748"},"wordCount":470,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=66748#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2901-1.webp","keywords":["Product approvals","Shionogi","TYO: 4507"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66748#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66748","url":"https:\/\/flcube.com\/?p=66748","name":"Shionogi's Symproic (Naldemedine) Receives NMPA Approval for Opioid-Induced Constipation in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=66748#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=66748#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2901-1.webp","datePublished":"2026-05-29T13:49:59+00:00","dateModified":"2026-05-29T13:50:00+00:00","description":"Shionogi & Co., Ltd. (TYO: 4507) announced that China's National Medical Products Administration (NMPA) has granted marketing approval for Symproic (naldemedine), an opioid-induced constipation (OIC) therapy. Naldemedine represents the world's first approved oral, peripherally acting selective mu-opioid receptor antagonist (PAMORA) and is now registered across major global markets including China, the United States, European Union, United Kingdom, and Japan.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66748#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66748"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=66748#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2901-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2901-1.webp","width":1080,"height":608,"caption":"Shionogi's Symproic (Naldemedine) Receives NMPA Approval for Opioid-Induced Constipation in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66748#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shionogi&#8217;s Symproic (Naldemedine) Receives NMPA Approval for Opioid-Induced Constipation in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2901-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66748","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66748"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66748\/revisions"}],"predecessor-version":[{"id":66751,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66748\/revisions\/66751"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/66750"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66748"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66748"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66748"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}